Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance-Reference-Cited by-同舟云学术

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance

Published:2008-03-09 Issue:3 Volume:112 Page:475-488
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Harvell Djuana M. E.,Spoelstra Nicole S.,Singh Meenakshi,McManaman James L.,Finlayson Christina,Phang Tzu,Trapp Susan,Hunter Lawrence,Dye Wendy W.,Borges Virginia F.,Elias Anthony,Horwitz Kathryn B.,Richer Jennifer K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-9897-4.pdf

Reference61 articles.

1. Ingle JN (2005) Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 11:900s–905s

2. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

3. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

4. Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116

5. Dowsett M, Cuzick J, Howell A, Jackson I (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 85:317–324

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid receptor regulates the epithelial-mesenchymal transition process through GR/ZEB1/E-cad and is involved in breast cancer endocrine drug resistance—a bioinformatics analysis;Translational Cancer Research;2023-11

2. High tumor copy number variations burden was associated with poor prognosis in patients with endocrine-resistant breast cancer;2023-08-24

3. Glucocorticoid receptor regulates the EMT process through GR/ZEB1/E-cad and is involved in breast cancer endocrine drug resistance;2023-06-05

4. Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER;Journal of Proteome Research;2023-05-12

5. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer;Biology;2023-05-09